Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib and Trastuzumab Biosimilar (Herzuma) in HER2 Mutated Advanced Solid Cancers
NCT06083662Phase 2Completed
- Sponsor
- Korea University Guro Hospital
- Start
- Jun 2021
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neratinib in solid tumor, sponsored by Korea University Guro Hospital. Primary endpoint: Overall Response Rate at 6 months. Started Jun 2021; status: completed.
02
Drugs
neratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06083662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083662.